Security key
40423R204
HCW Biologics Inc. - Common Stock, par value $0.0001 per share (HCWB)
CUSIP: 40423R204
Q2 2025 13F Holders as of 30 Jun 2025
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Total 13F shares
- 21,568
- Total 13F value
- $85,518
- Share change
- +21,568
- SEC-reported price per share
- $3.97
- Number of holders
- 8
- Value change
- +$85,518
- Number of buys
- 8
- Shares outstanding
- 7,087,776
Holder snapshot
5 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2025
Institutions
8
Top holders
8
HCWB full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2025
HCW Biologics Inc. SEC filings
HCW Biologics Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 40423R204
Recent filing periods:
Ownership snapshot
Top reported holders of HCWB - HCW Biologics Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Hing C. Wong
Disclosed value leader
Hing C. Wong
Comparable rows
1/15
Latest evidence
16 May 2025
13D/G
3/4/5
13F
Lead comparable stake: 23%
14 rows are not safely comparable across share classes.
13D/G row: Hing C. Wong
Showing 1-6 of 15 holder rows.
Quick read
Hing C. Wong leads the comparable SEC ownership view at 23%.
1 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Hing C. Wong's linked filing trail.
Comparable ownership
Top 1
Hing C. Wong
23%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Hing C. Wong |
13D/G
Hing C. Wong, Ph.D.
|
23%
|
$5,044,206
501,911 shares
|
$0 | 15 May 2025 |
| Peter Rhode |
3/4/5
Title of the Officer: Chief Scientific Officer and Vice President of Clinical Operations.
|
—
mixed-class rows
|
$161,061
136,354 shares
mixed-class rows
|
— | 11 Dec 2023 |
| Jin-An Jiao |
3/4/5
VP of Development
|
—
mixed-class rows
|
$93,812
51,998 shares
mixed-class rows
|
— | 31 May 2022 |
| Avantax Planning Partners, Inc. |
13F
Company
|
—
class O/S missing
|
$78,859
279,541 shares
|
— | 31 Mar 2025 |
| VANGUARD GROUP INC |
13F
Company
|
—
class O/S missing
|
$68,571
243,158 shares
|
— | 31 Mar 2025 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
—
class O/S missing
|
$66,864
236,967 shares
|
— | 31 Mar 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
8
Shares
21,568
Rows available
8
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2025 vs Q1 2026 Across Filers
Q1 2026 holders
14
Q2 2025 holders
8
Holder diff
-6
| Investor | Q1 2026 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend